Back to top
more

Rockwell Medical (RMTI)

(Delayed Data from NSDQ)

$1.00 USD

1.00
90,737

+0.01 (0.80%)

Updated Aug 5, 2025 04:00 PM ET

After-Market: $1.00 0.00 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (155 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

OraSure Technologies (OSUR) Reports Q2 Loss, Beats Revenue Estimates

by Zacks Equity Research

OraSure (OSUR) delivered earnings and revenue surprises of -26.67% and +2.62%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Rockwell Medical (RMTI) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Rockwell Medical (RMTI) delivered earnings and revenue surprises of -33.33% and 6.26%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Haemonetics (HAE) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Haemonetics (HAE) delivered earnings and revenue surprises of 1.64% and 1%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Rockwell Medical (RMTI) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Rockwell Medical (RMTI) delivered earnings and revenue surprises of -200% and 9.09%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

OraSure Technologies (OSUR) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

OraSure (OSUR) delivered earnings and revenue surprises of -200% and 2.27%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Rockwell Medical (RMTI) Surpasses Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Rockwell Medical (RMTI) delivered earnings and revenue surprises of 400% and 8.95%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Jushi Holdings Inc. (JUSHF) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Jushi Holdings Inc. (JUSHF) delivered earnings and revenue surprises of -100% and 5.99%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Urmimala Biswas headshot

RMTI Stock Rises 138% in Q3: What Should You Do Ahead of Earnings?

by Urmimala Biswas

Rockwell Medical expects its Q3 results to gain from a high rate of customer conversions toward it compared with its primary competitor.

Urmimala Biswas headshot

Rockwell Medical on Expansion Spree: Should You Buy the Stock Now?

by Urmimala Biswas

This year can be regarded as a momentous period for RMTI's business because this is the first time in its history that it has achieved steady revenue growth.

Zacks Equity Research

Rockwell Medical (RMTI) Upgraded to Buy: Here's Why

by Zacks Equity Research

Rockwell Medical (RMTI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

Amwell Shares Rise After Expansion of Portfolio With Hello Heart

by Zacks Equity Research

AMWL adds Hello Heart to its clinical programs, offering heart health solutions to members with high blood pressure or cholesterol via its Converge platform.

Zacks Equity Research

DaVita Stock Gains 47.3% Year to Date: What's Behind the Rally?

by Zacks Equity Research

DVA's strong performance and growth strategies, including patient-centric care and international expansion, position it well for continued success despite potential risks.

Zacks Equity Research

Merit Medical Stock Gains 24.7% Year to Date: What's Behind the Rally?

by Zacks Equity Research

MMSI shows strong growth momentum with a robust product portfolio and recent acquisitions, positioning itself well in competitive healthcare markets.

Zacks Equity Research

Trinity Biotech Shares Surge on Positive Pre-Pivotal Clinical CGM Trial

by Zacks Equity Research

TRIB announces positive results from its pre-pivotal clinical European trial for a next-gen continuous glucose monitor, setting the stage for further development in 2025.

Zacks Equity Research

Rockwell Medical, Inc. (RMTI) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

Rockwell Medical (RMTI) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Urmimala Biswas headshot

Rockwell Medical Stock Surges 108.5% YTD: Should You Snap it Up Now?

by Urmimala Biswas

RMTI continues to outperform its peers, banking on its focus on optimizing business to drive sustainable profitability and meaningful cash flow generation.

Zacks Equity Research

Rockwell Medical (RMTI) is a Great Momentum Stock: Should You Buy?

by Zacks Equity Research

Does Rockwell Medical (RMTI) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Equity Research

Why Fast-paced Mover Rockwell Medical (RMTI) Is a Great Choice for Value Investors

by Zacks Equity Research

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Rockwell Medical (RMTI) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.

Zacks Equity Research

Rockwell Medical, Inc. (RMTI) Hit a 52 Week High, Can the Run Continue?

by Zacks Equity Research

Rockwell Medical (RMTI) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

Rockwell Medical, Inc. (RMTI) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

Rockwell Medical (RMTI) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

Fast-paced Momentum Stock Rockwell Medical (RMTI) Is Still Trading at a Bargain

by Zacks Equity Research

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Rockwell Medical (RMTI) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.

Zacks Equity Research

Rockwell Medical (RMTI) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Rockwell Medical (RMTI) delivered earnings and revenue surprises of 125% and 12.26%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Jushi Holdings Inc. (JUSHF) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Jushi Holdings Inc. (JUSHF) delivered earnings and revenue surprises of 83.33% and 3.81%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

TG Therapeutics (TGTX) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

TG Therapeutics (TGTX) delivered earnings and revenue surprises of 200% and 11.12%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Evolus, Inc. (EOLS) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Evolus (EOLS) delivered earnings and revenue surprises of -75% and 2.85%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?